It is believed that antagonists of mu-opioid receptor may play a role in cancer progression since MOR activation is linked to tumor progression and MOR antagonism has been postulated as a potential target strategy for cancer treatment [11•, 16–18]. Here, OPRM1 is linked to cancer.